Willingness-To-Pay (WTP): The New-Old Kid on the Economic Evaluation Block

Canadian Journal of Nursing Research

Volumn 33, Issue 1, 2001, Pages 59-64

  Gafni, Amiram ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATTITUDE TO HEALTH; COST BENEFIT ANALYSIS; ECONOMICS; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMAN; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; STANDARD; TIME; TREATMENT OUTCOME;

ATTITUDE TO HEALTH; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; FINANCING, PERSONAL; HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SOCIAL VALUES; TIME FACTORS; TREATMENT OUTCOME; VALUE OF LIFE;

EID: 0035382742     PISSN: 08445621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Ben-Zion, U., & Gafni, A. (1983). Evaluation of public investment in health care: Is the risk irrelevant? Journal of Health Economics, 2, 161-165.
2. Diener, A., O'Brien, B., & Gafni, A. (1998). Health care contingent valuation studies: A review and classification of the literature. Health Economics, 7, 13-26.
3. Drummond, M., O'Brien, B., Stoddart, G., & Torrance, G.W. (1997). Methods for the economic evaluation of health care programs. Oxford: Oxford University Press.
4. Gafni, A. (1991). Using willingness-to-pay as a measure of benefits: What is the relevant question to ask in the context of public decision making about health care programs? Medical Care, 29, 1246-1252.
5. Gafni, A. (1997). Willingness-to-pay in the context of economic evaluation of healthcare programs: Theory and practice. American Journal of Managed Care, 3, S21-S32.
6. Gafni, A. (1998). Willingness-to-pay: What's in a name? Pharmacoeconomics, 14, 465-470.
7. Johannesson, M., & Jonsson, B. (1991). Economic evaluation in health care: Is there a role for cost benefit analysis? Health Policy, 17, 1-23.
8. Kenkel, D. (1997). On valuing morbidity, cost effectiveness analysis and being rude. Journal of Health Economics, 16, 121-128.
9. Klose, T. (1999). The contingent valuation method in health care. Health Policy, 47, 97-123.
10. Levine, M.N., Gafni, A., Markham, B., & MacFarlane, D. (1992). A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Annals of Internal Medicine, 117, 53-58.
11. Matthews, D.C., Birch, S., Gafni, A., & DiCenso, A. (1999). Willingness-to-pay for periodontal therapy: Development and testing of an instrument. Journal of Public Health Dentistry, 59, 44-51.
12. Mishan, E. (1971). Cost-benefit analysis. London: Allen & Unwin.
13. O'Brien, B., & Gafni, A. (1996). When do the dollars make sense? Toward a conceptual framework for contingent valuation studies in health care. Medical Decision Making, 16, 288-299.
14. O'Brien, B., Goeree, R., Gafni, A., Torrance, G.W., Pauly, M.V., Erder, H., Rusthoven, J., Weeks, J., Cahill, M., & LaMont, B. (1998). Assessing the value of a new pharmaceutical: A feasibility study of contingent valuation in managed care. Medical Care, 36, 370-384.
15. Weinstein, M.C., & Manning, W.G. (1997). Theoretical issues in cost effectiveness analysis. Journal of Health Economics, 16, 121-128.
16. Williams, A. (1983). The economic role of health indicators. In G. Teeling Smith (Ed.), Measuring the social benefit of medicine (pp. 63-68). London: Office of Health Technology Assessment.